GPT and type 2 diabetes mellitus: In patients with T2DM and MASLD (n=54), significant reductions in body weight, HbA1c, ALT, AST, and FIB-4 (baseline mean: 1.30) were observed six months after the switch from GLP-1Ra to tirzepatide [16].